| Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection N Sherina, A Piralla, L Du, H Wan, M Kumagai-Braesch, J Andréll, ... Med 2 (3), 281-295. e4, 2021 | 209 | 2021 |
| Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant F Zuo, H Abolhassani, L Du, A Piralla, F Bertoglio, L de Campos-Mata, ... Nature communications 13 (1), 2670, 2022 | 136 | 2022 |
| Immunity to SARS-CoV-2 up to 15 months after infection H Marcotte, A Piralla, F Zuo, L Du, I Cassaniti, H Wan, M Kumagai-Braesh, ... IScience 25 (2), 2022 | 54 | 2022 |
| SARS-CoV-2–specific B-and T-cell immunity in a population-based study of young Swedish adults S Björkander, L Du, F Zuo, S Ekström, Y Wang, H Wan, N Sherina, ... Journal of Allergy and Clinical Immunology 149 (1), 65-75. e8, 2022 | 34 | 2022 |
| Genomic characterization of lymphomas in patients with inborn errors of immunity X Ye, PJ Maglione, C Wehr, X Li, Y Wang, H Abolhassani, E Deripapa, ... Blood Advances 6 (18), 5403-5414, 2022 | 16 | 2022 |
| Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients W Ren, X Wang, M Yang, H Wan, X Li, X Ye, B Meng, W Li, J Yu, M Lei, ... Blood Advances 6 (9), 2731-2744, 2022 | 14 | 2022 |
| Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis W Ren, H Wan, SA Own, M Berglund, X Wang, M Yang, X Li, D Liu, X Ye, ... Leukemia 38 (3), 610-620, 2024 | 1 | 2024 |
| Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19 B Strunz, C Maucourant, A Mehta, H Wan, L Du, D Sun, P Chen, ... The Journal of Infectious Diseases, jiae036, 2024 | | 2024 |
